| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00415-016-8128-X |
| P698 | PubMed publication ID | 27142710 |
| P50 | author | Ralph P. Maguire | Q47817589 |
| P2093 | author name string | Eva Havrdová | |
| Anna Belova | |||
| Andrew Wright | |||
| Hideki Garren | |||
| Donald R Johns | |||
| Anne Tisserant | |||
| Alla Goloborodko | |||
| Erik Wallstroem | |||
| P2860 | cites work | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | Q22252938 |
| Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis | Q24681662 | ||
| Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study | Q28290823 | ||
| Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin | Q33415491 | ||
| CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes | Q36085387 | ||
| Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. | Q44671613 | ||
| Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study | Q44755697 | ||
| Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β. | Q45807781 | ||
| Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial | Q46467386 | ||
| Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial | Q46911236 | ||
| Secukinumab in plaque psoriasis--results of two phase 3 trials | Q49167189 | ||
| A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis | Q82763063 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1287-1295 | |
| P577 | publication date | 2016-05-03 | |
| P1433 | published in | Journal of Neurology | Q6295649 |
| P1476 | title | Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study | |
| P478 | volume | 263 |
| Q38373177 | A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease |
| Q55357541 | Androgen-Induced Immunosuppression. |
| Q90632651 | Assessment of Mitochondrial Dysfunction in Experimental Autoimmune Encephalomyelitis (EAE) Models of Multiple Sclerosis |
| Q38729214 | Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications |
| Q41005423 | CCR6+ Th cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic Th1 cells and GM-CSF-only-secreting Th cells. |
| Q46247849 | Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? |
| Q45071794 | Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications. |
| Q61810290 | Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence |
| Q57493087 | Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature |
| Q50142481 | European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. |
| Q92024647 | IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis |
| Q40231889 | IL-17-triggered downregulation of miR-497 results in high HIF-1α expression and consequent IL-1β and IL-6 production by astrocytes in EAE mice |
| Q52332793 | Inflammasome Proteins As Biomarkers of Multiple Sclerosis. |
| Q95856653 | Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development |
| Q62735530 | Interleukin-17-producing γδ T (γδ17) cells in inflammatory diseases |
| Q48556502 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. |
| Q38747100 | Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents |
| Q64091829 | Monoclonal Antibodies in Multiple Sclerosis: Present and Future |
| Q90701033 | Pathogenic T cell cytokines in multiple sclerosis |
| Q91449134 | Prophylactic treatment against GM-CSF, but not IL-17, abolishes relapses in a chronic murine model of multiple sclerosis |
| Q50587355 | Psoriasis comorbidity affects multiple sclerosis neurological progression: a retrospective case - control analysis. |
| Q88615583 | Reverse Translation for Assessment of Confidence in Animal Models of Multiple Sclerosis for Drug Discovery |
| Q64253580 | Shared Gene Expression Between Multiple Sclerosis and Ischemic Stroke |
| Q91277140 | Species differences in immune-mediated CNS tissue injury and repair: A (neuro)inflammatory topic |
| Q91706874 | Th17 and Cognitive Impairment: Possible Mechanisms of Action |
| Q38800522 | Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis |
| Q90134973 | When encephalitogenic T cells collaborate with microglia in multiple sclerosis |
| Q52689973 | When worlds collide: Th17 and Treg cells in cancer and autoimmunity. |
Search more.